Jeremy Chadwick Sells 2,039 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 2,039 shares of Kymera Therapeutics stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $88.93, for a total transaction of $181,328.27. Following the completion of the sale, the chief operating officer directly owned 77,729 shares of the company’s stock, valued at approximately $6,912,439.97. The trade was a 2.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Kymera Therapeutics Stock Performance

KYMR traded down $0.24 during midday trading on Wednesday, reaching $86.11. The company’s stock had a trading volume of 1,043,150 shares, compared to its average volume of 845,289. The company has a fifty day simple moving average of $78.69 and a 200 day simple moving average of $66.27. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same period in the previous year, the business posted ($0.88) earnings per share. The firm’s revenue was down 60.8% compared to the same quarter last year. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: UBS raised its price target to $128 and maintained a Buy rating, implying meaningful upside vs. the current level — this is a material analyst catalyst that can support upside interest. UBS price target raise
• Positive Sentiment: Analyst coverage and commentary highlight Kymera’s strong cash position (~$1.6B) and advancing degraders (KT‑621, KT‑579) into mid‑stage trials — these program milestones (2026–2027 catalysts) underpin medium‑term upside. Seeking Alpha pipeline write-up
• Positive Sentiment: Recent press roundups note broad analyst bullishness on select healthcare names including Kymera, which can help sustain investor interest from institutions and momentum traders. Globe and Mail analyst roundup
• Neutral Sentiment: Fundamentals remain mixed: recent quarterly results included a revenue shortfall and wider losses, which keep near‑term valuation sensitive to execution and clinical readouts. (Context referenced in analyst coverage above.) Seeking Alpha: financial context
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M) — a ~10.8% reduction in his holding — which is a notable insider disposition that may create near‑term selling pressure or prompt investor questions about timing. Bruce Booth Form 4
• Negative Sentiment: Multiple executive sales: CFO Bruce Jacobs, COO Jeremy Chadwick and insider Jared Gollob completed several transactions across March 2–4 totaling tens of thousands of shares at prices in the mid‑$80s to ~$90 — cumulative insider selling raises short‑term supply concerns. Insider filings

Wall Street Analyst Weigh In

Several analysts recently commented on KYMR shares. UBS Group raised their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. lifted their target price on Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. B. Riley Financial boosted their price objective on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Piper Sandler lifted their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Hedge Funds Weigh In On Kymera Therapeutics

Large investors have recently bought and sold shares of the company. Baker BROS. Advisors LP grew its holdings in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC grew its position in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after buying an additional 1,061,957 shares during the period. Finally, BVF Inc. IL lifted its stake in shares of Kymera Therapeutics by 6.6% in the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after acquiring an additional 340,909 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.